Abeona Therapeutics Inc. (NASDAQ:ABEO) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.

Several other research firms have also recently weighed in on ABEO. Jefferies Group LLC reissued a “buy” rating and set a $11.00 price objective on shares of Abeona Therapeutics in a report on Thursday, June 1st. FBR & Co reissued a “buy” rating on shares of Abeona Therapeutics in a report on Friday, March 10th. Cantor Fitzgerald reissued a “buy” rating and set a $21.00 price objective on shares of Abeona Therapeutics in a report on Friday, May 12th. Maxim Group set a $14.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a report on Thursday, May 25th. Finally, Zacks Investment Research raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, June 9th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $16.75.

Abeona Therapeutics (NASDAQ:ABEO) traded up 5.70% during midday trading on Thursday, hitting $8.35. 754,513 shares of the company were exchanged. Abeona Therapeutics has a 1-year low of $2.31 and a 1-year high of $9.44. The stock has a 50 day moving average of $5.54 and a 200 day moving average of $5.24. The firm’s market capitalization is $336.13 million.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Thursday, May 18th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02. Abeona Therapeutics had a negative net margin of 2,568.57% and a negative return on equity of 26.99%. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.28 million. On average, equities analysts predict that Abeona Therapeutics will post ($0.56) earnings per share for the current fiscal year.

WARNING: This piece of content was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/08/abeona-therapeutics-inc-abeo-raised-to-buy-at-bidaskclub.html.

A number of hedge funds have recently made changes to their positions in ABEO. Allianz Asset Management AG acquired a new stake in shares of Abeona Therapeutics during the fourth quarter worth approximately $236,000. A.R.T. Advisors LLC acquired a new stake in shares of Abeona Therapeutics during the fourth quarter worth approximately $117,000. Tudor Investment Corp Et Al acquired a new stake in shares of Abeona Therapeutics during the fourth quarter worth approximately $162,000. Highbridge Capital Management LLC boosted its stake in shares of Abeona Therapeutics by 108.1% in the fourth quarter. Highbridge Capital Management LLC now owns 551,800 shares of the biopharmaceutical company’s stock worth $2,676,000 after buying an additional 286,657 shares in the last quarter. Finally, Hikari Power Ltd acquired a new stake in shares of Abeona Therapeutics during the first quarter worth approximately $150,000. 35.84% of the stock is owned by institutional investors and hedge funds.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.